1 / 10

Counts

Supplemental Figure 1. A. B. 100. 100. 80. 80. 60. 60. Counts. Counts. 40. 40. 20. 20. 0. 0. TLR8-PE. TLR3-PE. C. 100. 80. 60. Counts. 40. 20. 0. TLR9-PE. Supplemental Figure 2. B. A. ***. **. 1.5. **. 50. **. 250. 40. 1. 200. No. of living cells

turner
Download Presentation

Counts

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplemental Figure 1 A B 100 100 80 80 60 60 Counts Counts 40 40 20 20 0 0 TLR8-PE TLR3-PE C 100 80 60 Counts 40 20 0 TLR9-PE

  2. Supplemental Figure 2 B A *** ** 1.5 ** 50 ** 250 40 1 200 No. of living cells (in million) 30 Percentage (apoptotic cells) 150 Counts 20 0.5 100 10 50 0 0 0 CL264+ Cisplatin CL264+ Cisplatin PBS PBS Cisplatin Cisplatin CL264 CL264 TLR7-PE

  3. Supplemental Figure 3 ** ns ns ** 14000 ** ** 12000 ** 10000 8000 Tumor volume (mm3 ) 6000 4000 2000 0 PBS CL264 Cisplatin(100µM) Cisplatin(200µM) Cisplatin(300µM) CL264+Cisplatin(100µM) CL264+Cisplatin(200µM) CL264+Cisplatin(300µM)

  4. Supplemental Figure 4 A B 7500 6000 4500 Tumor volume (mm3) day 28 3000 1500 0 CL264 Cisplatin IRS661 ODN - + - + - + - + - - + + - - + + - - - - + + + + + + + + - - - -

  5. Supplemental Figure 5 CD3+ T cells CD4+ T cells B A ns ns ns ns 15 100 20 40 80 15 30 10 60 nb CD3+ cells (x106) %CD3+ cells among CD45+ cells nb CD3+ CD4+ cells (x106) %CD3+ CD4+ cells among CD45+ cells 10 20 40 5 5 10 20 0 0 0 0 CL264 CL264 PBS PBS CL264 PBS CL264 PBS CD8+ T cells CD3+ Foxp3+TReg cells C D ns ns ns 1.5 ns 3 8 10 3 15 8 6 1 2 2 10 %CD3+ Foxp3+ cells among CD45+ cells 6 %CD3+ CD8+ cells among CD45+ cells 4 nb CD3+ Foxp3+ cells (x106) nb Gr1- CD11b+ cells (x106) nb CD3+ CD8+ cells (x106) 4 0.5 1 1 5 2 2 0 0 0 0 0 CL264 0 CL264 PBS CL264 PBS CL264 PBS PBS CL264 PBS CL264 PBS Gr1-CD11c+ dendritic cells Gr1-CD11b+ macrophages E F ** ** ** ** 60 20 15 40 %Gr1- CD11b+ cells among CD45+ cells %Gr1- CD11c+ cells among CD45+ cells nb Gr1- CD11c+ cells (x106) 10 20 5 0 0 CL264 PBS CL264 PBS Gr1+CD11b+ MDSCs G ** ** 40 1.5 30 1 %Gr1+ CD11b+ cells among CD45+ cells 20 nb Gr1+ CD11b+ cells (x106) 0.5 10 0 0 CL264 CL264 PBS PBS

  6. Supplemental Figure 6 P value Percentage of TLR7 expressingtumor cells

  7. Supplemental Figure 7 P value Percentage of TLR7 expressingtumor cells

  8. Supplemental Figure 8 1 • Responders =55/166 • Non-responders =111/166 • P = 0.00218 .8 .6 OverallSurvival (OS) .4 .2 0 0 20 40 60 80 100 120 Time(months)

  9. Supplemental Figure 9 100 80 60 R2= 0.5084 p= 0.0009 40 % TLR7 in tumor cells in LN afterchemotherapy 20 0 0 20 60 80 100 40 % TLR7 in tumor cells in lungafterchemotherapy

  10. Supplemental Figure 10 B LymphNode Downstaging 100 80 60 % TLR7 positive tumoral cells 100 40 A Tumor Downstaging 20 80 0 60 Yes No 40 % TLR7 positive tumoral cells 20 C 0 No Yes

More Related